posted on
May 06, 2020 11:59AM
...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Message: Re: RVXOT
Your Vote:
Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
KOO - Sorry! In your query you posted the description and said to note it so I thought you were referring to something in it. I have your answer now. They have mixed two companies up. They have used Zenith Capital Corp.'s description for Zenith Capital Corporation. They are ywo different companies that you can find both on SEDAR. Ours is Corp., not the whole word. ZENI.P is the whole word and is a Vancouver company incorporated in March 2019. The were just listed on the Venture Exchange and had a $200,000 IPO in March 2020.
RVXOT
March 6, 2020 – Vancouver, British Columbia - Zenith Capital Corporation (the “Corporation”) (TSX-V: ZENI.P), a capital pool company, is pleased to announce that it has successfully completed its initial public offering (the “Offering”) of 2,000,000 common shares (the “Shares”) for gross proceeds of $200,000 through its agent, Canaccord Genuity Corp. (the “Agent”). In connection with the Offering, the Corporation granted to the Agent non-transferable warrants to purchase up to 200,000 Shares at a price of $0.10 per Share, which may be exercised until March 6, 2022. The Agent also received a cash commission and an administration fee for its services in connection with the Offering. The net proceeds of the Offering will be used by the Corporation to identify and evaluate assets or businesses for acquisition with a view to completing a "Qualifying Transaction" under the Capital Pool Company program of the TSX Venture Exchange (the “Exchange”). The board of directors of the Corporation consists of Charalambos (Harry) Katevatis, Vivian Katsuris and Theo Sanidas. An aggregate of 400,000 stock options have also been granted to the directors and officers of the Corporation to acquire Shares of the Corporation at an exercise price of $0.10 per Share with an expiry date of March 6, 2025. The Shares were listed on the Exchange on March 6, 2020 and immediately halted pending closing of the Offering. The Shares are expected to commence trading on the Exchange on March 10, 2020 under the trading symbol “ZENI.P”. On behalf of the board of Zenith Capital Corporation Per: “Charalambos Katevatis” Charalambos Katevatis President, CEO, CFO, Corporate Secretary and Director
1 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply